Guardant Health, Inc. $GH Shares Sold by Castleark Management LLC

Castleark Management LLC trimmed its position in Guardant Health, Inc. (NASDAQ:GH) by 2.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 160,283 shares of the company’s stock after selling 4,760 shares during the quarter. Castleark Management LLC’s holdings in Guardant Health were worth $14,805,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Allworth Financial LP boosted its holdings in Guardant Health by 19.5% in the third quarter. Allworth Financial LP now owns 844 shares of the company’s stock worth $53,000 after purchasing an additional 138 shares during the period. Eastern Bank raised its holdings in shares of Guardant Health by 6.9% during the fourth quarter. Eastern Bank now owns 2,160 shares of the company’s stock worth $221,000 after purchasing an additional 139 shares during the period. First Pacific Financial raised its holdings in shares of Guardant Health by 33.1% during the first quarter. First Pacific Financial now owns 559 shares of the company’s stock worth $52,000 after purchasing an additional 139 shares during the period. Xponance LLC raised its holdings in shares of Guardant Health by 2.1% during the fourth quarter. Xponance LLC now owns 9,630 shares of the company’s stock worth $984,000 after purchasing an additional 199 shares during the period. Finally, Danske Bank A S lifted its position in shares of Guardant Health by 20.0% in the 4th quarter. Danske Bank A S now owns 1,200 shares of the company’s stock worth $123,000 after buying an additional 200 shares during the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on GH shares. Mizuho lifted their price target on shares of Guardant Health from $135.00 to $175.00 and gave the company an “outperform” rating in a report on Monday, June 8th. The Goldman Sachs Group assumed coverage on shares of Guardant Health in a research note on Friday, June 5th. They set a “buy” rating and a $165.00 price objective on the stock. JPMorgan Chase & Co. raised their target price on shares of Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Citigroup lifted their target price on Guardant Health from $150.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $160.04.

Guardant Health Stock Performance

Guardant Health stock opened at $147.33 on Monday. The company has a 50-day simple moving average of $139.41 and a 200-day simple moving average of $112.02. The firm has a market capitalization of $19.54 billion, a P/E ratio of -43.46 and a beta of 1.59. Guardant Health, Inc. has a one year low of $40.35 and a one year high of $174.08.

Insider Transactions at Guardant Health

In other Guardant Health news, Director Myrtle S. Potter sold 1,556 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $131.16, for a total transaction of $204,084.96. Following the completion of the transaction, the director directly owned 20,971 shares of the company’s stock, valued at $2,750,556.36. The trade was a 6.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Amirali Talasaz sold 143,028 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $151.54, for a total transaction of $21,674,463.12. Following the completion of the sale, the chief executive officer owned 1,881,336 shares in the company, valued at $285,097,657.44. The trade was a 7.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 708,565 shares of company stock worth $90,556,597 over the last 90 days. Corporate insiders own 5.60% of the company’s stock.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.